Skye Bioscience Reports Promising Clinical Trial Results for Obesity Treatment Combination
Skye Bioscience announced positive clinical trial results for nimacimab, a peripherally-restricted CB1 inhibitor antibody, when combined with semaglutide in treating obesity. The Phase 2a CBeyond study demonstrated a significant 22.3% total weight loss at 52 weeks, highlighting a potentially innovative approach to metabolic health disorders.
Trial Design and Outcomes
The blinded extension study involved 41 participants, with 21 in the combination therapy arm and 20 in the placebo arm. Participants received nimacimab (200 mg) in combination with semaglutide (2.4 mg), with researchers tracking weight loss and metabolic parameters over 52 weeks.
Key findings include:
- 22.3% total weight loss in the nimacimab + semaglutide group
- No observed weight loss plateau
- Reduced weight regain during treatment interruption
- Strong safety and tolerability profile
Notably, participants in the combination therapy group regained only 17.8% of lost weight during a 13-week off-therapy period, compared to 37.3% weight regain in the semaglutide-alone group.
Research Context and Mechanism
Nimacimab represents a novel approach to obesity treatment by targeting the CB1 receptor peripherally. Unlike previous CB1-targeted drugs, this monoclonal antibody is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects associated with earlier compounds.
The molecule acts independently of the GLP-1 pathway, offering a complementary mechanism to existing obesity treatments. Preclinical and early clinical studies suggest additive effects when combined with incretin-based therapies like semaglutide.
Competitive Landscape
The obesity treatment market continues to evolve, with several key competitors: